$Connect Biopharma (CNTB.US)$ NEWS Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
$Connect Biopharma (CNTB.US)$Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
James Huang's appointment to Connect Biopharma's Board of Directors is viewed positively, with his vast biotech and investment experience anticipated to offer unique insights and aid the company's pipeline progression.
Connect Biopharma Stock Forum
NEWS
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
Price target for this stock is 7$ its undervalued .. sooner it will jump to 2.5 to 3$
No comment yet